Bulletin
Investor Alert

Alkermes PLC

NAS: ALKS

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Mar 5, 2021, 4:02 p.m.

/zigman2/quotes/205084517/composite

$

19.28

Change

0.00 0.00%

Volume

Volume 17,908

Quotes are delayed by 20 min

/zigman2/quotes/205084517/composite

Previous close

$ 18.21

$ 19.28

Change

+1.07 +5.88%

Day low

Day high

$18.02

$19.34

Open

52 week low

52 week high

$11.98

$23.92

Open

Company Description

Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adul...

Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.

Valuation

Price to Sales Ratio

3.05

Price to Book Ratio

2.98

Price to Cash Flow Ratio

31.96

Enterprise Value to Sales

2.83

Total Debt to Enterprise Value

0.14

Efficiency

Revenue/Employee

462,698.00

Income Per Employee

-49,381.00

Receivables Turnover

3.74

Total Asset Turnover

0.55

Liquidity

Current Ratio

2.53

Quick Ratio

2.25

Cash Ratio

1.45

Profitability

Gross Margin

77.58

Operating Margin

-10.82

Pretax Margin

-9.29

Net Margin

-10.67

Return on Assets

-5.90

Return on Equity

-10.30

Return on Total Capital

-7.88

Return on Invested Capital

-7.85

Capital Structure

Total Debt to Total Equity

38.44

Total Debt to Total Capital

27.77

Total Debt to Total Assets

21.04

Long-Term Debt to Equity

36.70

Long-Term Debt to Total Capital

26.51

Officers and Executives

Name Age Officer Since Title
Mr. Richard F. Pops 56 1991 Chief Executive Officer & Director
Mr. Blair C. Jackson 46 1999 Senior Vice President-Corporate Planning
Mr. Iain Michael Brown 50 2003 Chief Accounting Officer & Senior VP-Finance
Ms. Sondra Smyrnios - 2019 Senior Vice President-Clinical Operations
Dr. Kanchan Relwani - 2017 Senior Vice President-Medical Affairs

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
02/21/2021 Richard F. Pops
Director and CEO, Alkermes plc; Director
14,386   Derivative/Non-derivative trans. at $19.58 per share. 281,677
02/21/2021 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc.
2,587   Derivative/Non-derivative trans. at $19.58 per share. 50,653
02/21/2021 David Jose Gaffin
SVP, CLO, Alkermes, Inc.
2,022   Derivative/Non-derivative trans. at $19.58 per share. 39,590
02/21/2021 Blair C. Jackson
EVP, Chief Operating Officer
1,412   Derivative/Non-derivative trans. at $19.58 per share. 27,646
02/21/2021 Iain Michael Brown
SVP, Chief Financial Officer
1,412   Derivative/Non-derivative trans. at $19.58 per share. 27,646
02/21/2021 Craig C. Hopkinson
EVP R&D, Chief Medical Officer
2,022   Derivative/Non-derivative trans. at $19.58 per share. 39,590
02/21/2021 Richard F. Pops
Director and CEO, Alkermes plc; Director
32,400   Derivative/Non-derivative trans. at $0 per share. 0
02/21/2021 David Jose Gaffin
SVP, CLO, Alkermes, Inc.
6,875   Derivative/Non-derivative trans. at $0 per share. 0
02/21/2021 Blair C. Jackson
EVP, Chief Operating Officer
4,800   Derivative/Non-derivative trans. at $0 per share. 0
02/21/2021 Iain Michael Brown
SVP, Chief Financial Officer
4,800   Derivative/Non-derivative trans. at $0 per share. 0
02/21/2021 Craig C. Hopkinson
EVP R&D, Chief Medical Officer
6,875   Derivative/Non-derivative trans. at $0 per share. 0
02/20/2021 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc.
5,825   Derivative/Non-derivative trans. at $0 per share. 0
02/20/2021 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc.
5,353   Derivative/Non-derivative trans. at $0 per share. 0
02/20/2021 David Jose Gaffin
SVP, CLO, Alkermes, Inc.
7,036   Derivative/Non-derivative trans. at $0 per share. 0
02/20/2021 Blair C. Jackson
EVP, Chief Operating Officer
4,589   Derivative/Non-derivative trans. at $0 per share. 0
02/20/2021 Iain Michael Brown
SVP, Chief Financial Officer
4,589   Derivative/Non-derivative trans. at $0 per share. 0
02/20/2021 Craig C. Hopkinson
EVP R&D, Chief Medical Officer
10,095   Derivative/Non-derivative trans. at $0 per share. 0
02/20/2021 C. Todd Nichols
SVP, Chief Commercial Officer
3,824   Derivative/Non-derivative trans. at $0 per share. 0
02/20/2021 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc.
2,360   Derivative/Non-derivative trans. at $19.58 per share. 46,208
02/20/2021 David Jose Gaffin
SVP, CLO, Alkermes, Inc.
2,061   Derivative/Non-derivative trans. at $19.58 per share. 40,354
02/20/2021 Blair C. Jackson
EVP, Chief Operating Officer
1,374   Derivative/Non-derivative trans. at $19.58 per share. 26,902
02/20/2021 Iain Michael Brown
SVP, Chief Financial Officer
1,378   Derivative/Non-derivative trans. at $19.58 per share. 26,981
02/20/2021 Craig C. Hopkinson
EVP R&D, Chief Medical Officer
3,064   Derivative/Non-derivative trans. at $19.58 per share. 59,993
02/20/2021 C. Todd Nichols
SVP, Chief Commercial Officer
1,292   Derivative/Non-derivative trans. at $19.58 per share. 25,297
02/17/2021 Richard F. Pops
Director and CEO, Alkermes plc; Director
3,869   Derivative/Non-derivative trans. at $19.97 per share. 77,263
02/17/2021 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc.
1,492   Derivative/Non-derivative trans. at $19.97 per share. 29,795
02/17/2021 David Jose Gaffin
SVP, CLO, Alkermes, Inc.
868   Derivative/Non-derivative trans. at $19.97 per share. 17,333
02/17/2021 Blair C. Jackson
EVP, Chief Operating Officer
781   Derivative/Non-derivative trans. at $19.97 per share. 15,596
02/17/2021 Iain Michael Brown
SVP, Chief Financial Officer
868   Derivative/Non-derivative trans. at $19.97 per share. 17,333
02/17/2021 Richard F. Pops
Director and CEO, Alkermes plc; Director
8,750   Derivative/Non-derivative trans. at $0 per share. 0
02/17/2021 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc.
3,000   Derivative/Non-derivative trans. at $0 per share. 0
02/17/2021 David Jose Gaffin
SVP, CLO, Alkermes, Inc.
2,500   Derivative/Non-derivative trans. at $0 per share. 0
02/17/2021 Blair C. Jackson
EVP, Chief Operating Officer
2,250   Derivative/Non-derivative trans. at $0 per share. 0
02/17/2021 Iain Michael Brown
SVP, Chief Financial Officer
2,500   Derivative/Non-derivative trans. at $0 per share. 0
02/16/2021 Richard F. Pops
Director and CEO, Alkermes plc; Director
8,074   Derivative/Non-derivative trans. at $19.79 per share. 159,784
02/16/2021 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc.
1,678   Derivative/Non-derivative trans. at $19.79 per share. 33,207
02/16/2021 David Jose Gaffin
SVP, CLO, Alkermes, Inc.
1,172   Derivative/Non-derivative trans. at $19.79 per share. 23,193
02/16/2021 Blair C. Jackson
EVP, Chief Operating Officer
825   Derivative/Non-derivative trans. at $19.79 per share. 16,326
02/16/2021 Iain Michael Brown
SVP, Chief Financial Officer
825   Derivative/Non-derivative trans. at $19.79 per share. 16,326
02/16/2021 Craig C. Hopkinson
EVP R&D, Chief Medical Officer
1,172   Derivative/Non-derivative trans. at $19.79 per share. 23,193
02/16/2021 Richard F. Pops
Director and CEO, Alkermes plc; Director
18,125   Derivative/Non-derivative trans. at $0 per share. 0
02/16/2021 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc.
3,375   Derivative/Non-derivative trans. at $0 per share. 0
02/16/2021 David Jose Gaffin
SVP, CLO, Alkermes, Inc.
3,375   Derivative/Non-derivative trans. at $0 per share. 0
02/16/2021 Blair C. Jackson
EVP, Chief Operating Officer
2,375   Derivative/Non-derivative trans. at $0 per share. 0
02/16/2021 Iain Michael Brown
SVP, Chief Financial Officer
2,375   Derivative/Non-derivative trans. at $0 per share. 0
02/16/2021 Craig C. Hopkinson
EVP R&D, Chief Medical Officer
3,375   Derivative/Non-derivative trans. at $0 per share. 0
01/13/2021 Wendy L. Dixon
Director
20,000   Derivative/Non-derivative trans. at $12.62 per share. 252,400
01/13/2021 Wendy L. Dixon
Director
15,000   Derivative/Non-derivative trans. at $12.62 per share. 189,300
10/01/2020 Paul J. Mitchell
Director
20,000   Disposition at $16.61 per share. 332,200
10/01/2020 Paul J. Mitchell
Director
20,000   Derivative/Non-derivative trans. at $14.92 per share. 298,400
09/28/2020 David Westbrook Anstice
Director
17,832   Disposition at $16.78 per share. 299,220
09/28/2020 David Westbrook Anstice
Director
20,000   Derivative/Non-derivative trans. at $14.92 per share. 298,400
07/14/2020 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc.
5,523   Derivative/Non-derivative trans. at $18.1 per share. 99,966
06/07/2020 Craig C. Hopkinson
EVP R&D, Chief Medical Officer
368   Derivative/Non-derivative trans. at $17.19 per share. 6,325
06/07/2020 Craig C. Hopkinson
EVP R&D, Chief Medical Officer
1,250   Derivative/Non-derivative trans. at $0 per share. 0
06/05/2020 David Jose Gaffin
SVP, CLO, Alkermes, Inc.
1,000   Gift at $0 per share. 0
06/05/2020 C. Todd Nichols
SVP, Chief Commercial Officer
1,029   Derivative/Non-derivative trans. at $17.19 per share. 17,688
06/05/2020 C. Todd Nichols
SVP, Chief Commercial Officer
3,500   Derivative/Non-derivative trans. at $0 per share. 0
/news/latest/company/us/alks

MarketWatch News on ALKS

  1. The Case for AbbVie as a Top Biopharma Stock in 2021

    8:45 a.m. Jan. 7, 2021

    - Barron's Online

  2. Alkermes upgraded to buy from neutral at Mizuho

    5:35 a.m. Oct. 15, 2020

    - Tomi Kilgore

  3. Alkermes stock price target raised to $24 from $19 at Mizuho

    5:04 a.m. Oct. 15, 2020

    - Tomi Kilgore

  4. Alkermes downgraded to neutral from buy at BofA Securities

    10:40 a.m. Feb. 14, 2020

    - Tomi Kilgore

  5. Alkermes stock price target cut to $20 from $31 at BofA Securities

    10:40 a.m. Feb. 14, 2020

    - Tomi Kilgore

  6. Alkermes downgraded to neutral from overweight at J.P. Morgan

    7:51 a.m. Feb. 14, 2020

    - Tomi Kilgore

  7. Alkermes stock price target cut to $21 from $25 at J.P. Morgan

    7:52 a.m. Feb. 14, 2020

    - Tomi Kilgore

  8. FDA told Alkermes to stop publishing Vivitrol ad

    12:12 p.m. Dec. 11, 2019

    - Jaimy Lee

  9. Alkermes to acquire Rodin Therapeutics for up to $950 million

    7:30 a.m. Nov. 18, 2019

    - Ciara Linnane

  10. Biogen shares fall 3%

    3:08 p.m. Nov. 14, 2019

    - Jaimy Lee

  11. Biogen, Alkermes MS treatment Vumerity gets FDA approval

    6:33 a.m. Oct. 30, 2019

    - Tomi Kilgore

  12. Alkermes upgraded to equal weight at Morgan Stanley

    9:09 a.m. Sept. 5, 2019

    - Tomi Kilgore

  13. Alkermes stock price target cut to $34 from $40 at Stifel Nicolaus

    7:55 a.m. Feb. 15, 2019

    - Tomi Kilgore

  14. Alkermes shares fall after FDA blocks antidepressant approval

    4:56 p.m. Feb. 1, 2019

    - Wallace Witkowski

  15. Alkermes reports positive results in late-stage trial of schizophrenia treatment

    7:01 a.m. Nov. 29, 2018

    - Ciara Linnane

  16. Loading more headlines...
/news/nonmarketwatch/company/us/alks

Other News on ALKS

  1. Top Stocks To Buy On The Sell-Off

    7:38 a.m. Feb. 28, 2021

    - Seeking Alpha

  2. 10-K: ALKERMES PLC.

    5:06 p.m. Feb. 11, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  3. Alkermes plc 2020 Q4 - Results - Earnings Call Presentation

    12:09 p.m. Feb. 11, 2021

    - Seeking Alpha

  4. Alkermes (ALKS) Beats Q4 Earnings and Revenue Estimates

    8:35 a.m. Feb. 11, 2021

    - Zacks.com

  5. Alkermes Q4 topline slumps, provides 2021 forecast

    8:19 a.m. Feb. 11, 2021

    - Seeking Alpha

  6. Alkermes Q4 2020 Earnings Preview

    12:28 p.m. Feb. 10, 2021

    - Seeking Alpha

  7. Notable earnings before Thursday's open

    12:27 p.m. Feb. 10, 2021

    - Seeking Alpha

  8. Top Heavily-Shorted Stocks You Can Buy Now

    2:15 p.m. Feb. 4, 2021

    - Seeking Alpha

  9. Ultragenyx's (RARE) IND for Wilson Disease Cleared by FDA

    9:02 a.m. Jan. 22, 2021

    - Zacks.com

  10. AstraZeneca's (AZN) Enhertu Gets EU Nod for Breast Cancer

    7:14 a.m. Jan. 21, 2021

    - Zacks.com

  11. Alkermes (ALKS) Gets a Hold Rating from J.P. Morgan

    4:06 a.m. Jan. 20, 2021

    - SmarterAnalyst

  12. Loading more headlines...

At a Glance

Alkermes Plc

Connaught House

1 Burlington Road

Dublin, Dublin 4

Phone

353 17728000

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$1.04B

Net Income

$-110.86M

Employees

2,245

/news/pressrelease/company/us/alks

Press Releases on ALKS

  1. Alkermes to Hold Virtual Investor Day

    8:00 a.m. March 4, 2021

    - PR Newswire - PRF

  2. Loading more headlines...
Link to MarketWatch's Slice.